Gilead, which has had to face down some withering criticism in recent days, got a nice win at the FDA to boast about. The agency handed out their priority review track for the big biotech?s second CAR-T, KTE-X19.
The drug ? part of their CAR-T camp at Kite ? is being squired through a quick 6-month review for relapsed or drug-resistant mantle cell lymphoma, likely indicating that Richard Pazdur?s oncology team is ready to hand out a swift stamp of approval.